COVID-19 antibody ‘cocktail’ protects chronically ill: study

A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy
Skip to content